The NRFC has made a $32 million investment in Harrison.ai that will be used to further develop its suite of radiology and pathology diagnostics. The investment will also assist Harrison.ai in continuing to expand its services into other hospitals and healthcare facilities in Australia and around the world.
The NRFC’s investment will significantly improve health and economic outcomes, with Harrison.ai’s technology providing medical professionals with a powerful tool to support the detection and diagnosis of medical conditions quickly and accurately. The investment will also support Harrison.ai in continuing to base its operations in Australia, while ensuring that the employment opportunities created as it expands benefit Australian engineers, clinical AI experts, research professionals and others working in the local healthtech and ICT sectors.
About Harrison.ai
Harrison.ai is a Sydney-based global healthtech company that uses state-of-the art AI and partnerships with healthcare specialists to create diagnostic solutions that help solve healthcare capacity challenges.
Harrison.ai’s pioneering technology uses AI to review CT scans and X-rays to support the detection and diagnosis of medical conditions. The company’s technology enables clinicians to detect cases of cancer and other illnesses quickly and accurately. This significantly increases the number of treatable cases and the survivability of patients. Harrison.ai’s technology assists clinicians, providing them with a second set of eyes to help improve patient outcomes.
Harrison.ai’s proprietary AI solutions can detect up to 124 findings on chest X-rays and up to 130 findings on non-contrast head CTs. Harrison.ai’s software is currently live in over 1,000 healthcare facilities around the world, including the UK’s National Health Service. It is supporting the care of more than 6 million patients per year globally.
Investment impact
Improving health and economic outcomes
Harrison.ai’s world-leading AI technology is at the forefront of AI medical diagnostic support. It is helping to address the global shortage of radiologists and pathologists by providing early diagnosis support, increasing diagnostic accuracy and improving efficiencies.
The NRFC’s investment in Harrison.ai will allow the company to further develop its suite of radiology and pathology diagnostics and expand its services into more hospitals and healthcare facilities in Australia and around the world. This will have significant benefits for the diagnosis and treatment of serious medical conditions and for overall patient outcomes.
Commercialising Australian innovation
Harrison.ai’s technology was developed in Sydney by its co-founders, Dr Aengus Tran and Dimitry Tran. The NRFC’s investment is supporting Harrison.ai’s world-leading technology and helping to ensure that the company continues to base its operations in Australia.
Creating jobs
The expansion of Harrison.ai’s business enabled by the NRFC’s investment will create new jobs in the high-tech medical and ICT sectors. These could include increased opportunities for Australian engineers, clinical AI experts and research professionals.